Stocks Celgene Corp

More

  • US STOCKS-Futures higher as crude extends recovery Wednesday, 23 Dec 2015 | 7:29 AM ET

    Dec 23- U.S. stock index futures were higher on Wednesday as crude oil prices continued to rebound and investors awaited a slew of economic data. *The Commerce Department will publish the full report, which includes income and inflation data, at 8:30 a.m. ET. *Other data scheduled for Wednesday includes the University of Michigan's consumer sentiment index,...

  • Markets seek to continue pre-Christmas win streak Wednesday, 23 Dec 2015 | 6:42 AM ET

    Futures are pointing to a higher open on Wall Street this morning, as Wall Street aims for a third straight session of gains.

  • After-hours buzz: Nike, Celgene, Micron and more Tuesday, 22 Dec 2015 | 6:28 PM ET

    Check out the companies making headlines after the bell Tuesday: Nike, Micron Technology, Baxalta & more.

  • Dec 22- Celgene Corp said it would allow for the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States over a year before patents covering the drug expire. The company said it would provide India- based Natco Pharma Ltd and its U.S. partner, Arrow International Limited, a unit of Allergan Plc, the license to Celgene's patents...

  • Dec 22- Celgene Corp said it would allow the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States more than a year before the drug's patent expires. The company said it would allow India- based Natco Pharma Ltd and its U.S. partner to market an unlimited quantity of generic Revlimid beginning Jan. 31, 2026 as part of a patent...

  • *AstraZeneca confirms talks with biotech firm Acerta. LONDON, Dec 14- AstraZeneca said on Monday it was in talks that might lead to the acquisition of privately held biotech firm Acerta Pharma, a potential $5 billion- plus deal designed to build up its cancer drug portfolio. "AstraZeneca confirms that it is exploring potential strategic options with Acerta...

  • Cramer: Sellers just don't understand the game Tuesday, 8 Dec 2015 | 6:12 PM ET
    A Boeing 747-8 Intercontinental airliner

    Jim Cramer looks at the stock market like a card game, and investors just aren't dealing with the cards they have right now.

  • Oil falls towards 2015 low on OPEC inaction Monday, 7 Dec 2015 | 7:12 AM ET

    Meanwhile, U.S. stock futures were higher this morning, after the Dow surged 369 points, after Friday's solid jobs report and as ECB President Mario Draghi reassured markets.

  • Doctors fear a record level in FDA drug approvals Wednesday, 2 Dec 2015 | 7:00 AM ET
    Prescription drugs

    An FDA rule created to spur drug companies to develop treatments for rare diseases is being used far beyond its original scope, critics say.

  • Nov 30- The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone.

  • Chart analyst: This group is poised to rally Friday, 27 Nov 2015 | 11:03 AM ET
    Trader on the floor of the New York Stock Exchange.

    Mark Newton, chief technical analyst at Greywolf Execution Partners, shares his top investment idea for the months ahead.

  • Will rate hike ruin Santa Claus rally?: Insana Tuesday, 24 Nov 2015 | 9:37 AM ET
    Santa Claus waves to the crowd during the Macy's Thanksgiving Day Parade on November 27, 2014 in New York City.

    Here's how the Fed could play Grinch and wreck the Santa Claus rally, says Ron Insana.

  • *Denmark's Genmab scores important win with new cancer drug. Shares in Genmab, already up 130 percent this year, leapt a further 12 percent on news that the drug, which was licensed to Johnson& Johnson in 2012, had won early U.S. approval, lifting Genmab's market value to around $7 billion. Still, with several analysts forecasting peak annual sales for Darzalex of $5...

  • Nov 17- Shares in Genmab jumped 11 percent on Tuesday after U.S. regulators approved an experimental blood cancer drug that the Danish biotech company licensed in 2012 to Johnson& Johnson. The U.S. Food and Drug Administration said late on Monday it had approved Darzalex for patients who had already undergone at least three prior standard treatments for...

  • Lightning Round: I do not want to be in this group Monday, 9 Nov 2015 | 7:05 PM ET
    Mad Money Lightning Round

    Jim Cramer rattles off his take on caller favorite stocks, including his warning about this group that could be downhill for the holidays.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed mildly lower Thursday as investors awaited Friday's key jobs report that could shed light on the timing of a rate hike.

  • Nov 5- U.S. stocks slipped on Thursday, weighed down by energy and healthcare shares and a disappointing report from Qualcomm ahead of Friday's U.S. jobs report. Qualcomm was the biggest drag on the S&P 500, falling 16.7 percent after the chipmaker forecast first-quarter profit below expectations, while biotech Celgene fell 5.4 percent after its quarterly...

  • Facebook rose as much as 6.5 percent to $110.65 and gave the biggest boost to the S&P and Nasdaq. A U.S. Senate panel on Wednesday launched a probe into eye-popping drug price increases, seeking documents from four drugmakers including Valeant. Valeant shares sank 18.5 percent to $74.90.

  • Facebook rose 6.5 percent to $110.65 and gave the biggest boost to the S&P and Nasdaq. A U.S. Senate panel on Wednesday launched a probe into eye-popping drug price increases, seeking documents from four drugmakers including Valeant. The probe was affecting the entire biotech group and broader market as well, said Larry Peruzzi, a senior equity trader at Cabrera...

  • *Q3 profit $1.23/ shr vs. est. Nov 5- Celgene Corp posted its smallest revenue growth in five quarters due to slower sales of its two key cancer drugs. Growing sales of expensive new cancer drugs and other treatments helped top U.S. drugmakers such as Pfizer Inc, Merck& Co and Bristol-Myers Squibb Co post stronger-than-expected quarterly profits last month.